产品
编 号：F745248
分子式：C153H252N44O43
分子量：3395.91
分子式：C153H252N44O43
分子量：3395.91
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 1445155-39-4
产品详情
生物活性：
MR 409 is a selected growth hormone-releasing hormone (GHRH) agonist. MR 409 has remarkable neuroprotective effects through enhancing endogenous neurogenesis in cerebral ischemic mice. MR 409 also inhibits the in vivo growth of lung cancer.
体内研究：
MR 409 (MR-409) inhibits the in vivo growth of lung cancer xenografted into nude mice.MR 409 (5 μg; s.c. treated daily for 4 weeks) reduces nociceptive response in mice.Animal Model:Adult C57/BL6 male mice (5 weeks old, weight 20-22 g)
Dosage:5 μg
Administration:Treated daily by subcutaneous (s.c.) administration of 0.1 mL solution
Result:Showed maximal antinociceptive effects at 2 weeks. Sustained a moderate analgesic effect at 4 weeks.
体外研究：
One week post-myocardial infarction (MI), MR 409 (MR-409) significantly reduces plasma levels of IL-2, IL-6, IL-10 and TNF-α compared to placebo.MR 409 (MR-409; 1 μM) suppresses p53 expression in bovine pulmonary arterial endothelial cells (BPAECs).MR 409 (1 μM) induces the activation of JAK2, STAT3 and ERK1/2.MR 409 (MR-409; 1 and 5 μM) decreases LPS-induced PGE2 and 8-iso-PGF2α levels, in a dose-dependent manner. MR 409 (1 and 5μM) decreases LPS-induced lactate dehydrogenase (LDH) activity and nitrite production, without showing a dose-dependent effect. MR 409 (1 and 5 μM) decreases LPS-induced gene expression of COX-2, NF-κB and iNOS in colon specimens, without a dose-dependent effect. MR 409 (MR-409) can stimulate endogenous neurogenesis and improve the tMCAO-induced loss of neuroplasticity. MR 409 also enhances the proliferation and inhibits apoptosis of neural stem cells treated with oxygen and glucose deprivation-reperfusion.
MR 409 is a selected growth hormone-releasing hormone (GHRH) agonist. MR 409 has remarkable neuroprotective effects through enhancing endogenous neurogenesis in cerebral ischemic mice. MR 409 also inhibits the in vivo growth of lung cancer.
体内研究：
MR 409 (MR-409) inhibits the in vivo growth of lung cancer xenografted into nude mice.MR 409 (5 μg; s.c. treated daily for 4 weeks) reduces nociceptive response in mice.Animal Model:Adult C57/BL6 male mice (5 weeks old, weight 20-22 g)
Dosage:5 μg
Administration:Treated daily by subcutaneous (s.c.) administration of 0.1 mL solution
Result:Showed maximal antinociceptive effects at 2 weeks. Sustained a moderate analgesic effect at 4 weeks.
体外研究：
One week post-myocardial infarction (MI), MR 409 (MR-409) significantly reduces plasma levels of IL-2, IL-6, IL-10 and TNF-α compared to placebo.MR 409 (MR-409; 1 μM) suppresses p53 expression in bovine pulmonary arterial endothelial cells (BPAECs).MR 409 (1 μM) induces the activation of JAK2, STAT3 and ERK1/2.MR 409 (MR-409; 1 and 5 μM) decreases LPS-induced PGE2 and 8-iso-PGF2α levels, in a dose-dependent manner. MR 409 (1 and 5μM) decreases LPS-induced lactate dehydrogenase (LDH) activity and nitrite production, without showing a dose-dependent effect. MR 409 (1 and 5 μM) decreases LPS-induced gene expression of COX-2, NF-κB and iNOS in colon specimens, without a dose-dependent effect. MR 409 (MR-409) can stimulate endogenous neurogenesis and improve the tMCAO-induced loss of neuroplasticity. MR 409 also enhances the proliferation and inhibits apoptosis of neural stem cells treated with oxygen and glucose deprivation-reperfusion.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备